Cataract after stem cell transplantation
| Reference . | Type of study . | Patients (N) . | Probability of cataract formation . | Remarks . | ||
|---|---|---|---|---|---|---|
| sTBI . | fTBI . | No TBI . | ||||
| Deeg et al26 | Single center (Seattle) | 277 | 80% at 6 y | 18% at 6 y | 19% at 6 y | Sparing effect of fTBI |
| Tichelli et al27 | Single center (Basel) | 197 | 100% at 3.5 y; surgery 96% | 29% at 3.3 y | TBI | |
| Single dose | ||||||
| 83% at 6 y | Corticosteroids > 3 mo | |||||
| Benyunes et al28 | Single center (Seattle) | 492 | 85% at 11 y | Risk at 11 y 50% (> 12 Gy) | 19% at 11 y | Need of surgical repair 59% sTBI |
| 34% (12 Gy) | 33% fTBI | |||||
| 23% no TBI | ||||||
| Highest yearly hazard of cataract formation earlier with sTBI than fTBI | ||||||
| Belkacemi et al29 | Single center (Paris) | 494 | 34% at 5 y | 11% at 5 y | High dose rate, main risk factor | |
| Belkacemi et al30 | EBMT registry | 1063 | Risk at 10 y 60%; 32% surgery | Risk at 10 y 43%; 3% surgery | — | Risk factors Older age |
| Higher dose rate | ||||||
| Allogeneic SCT | ||||||
| No heparin | ||||||
| Socié et al31 | 4 randomized studies | 488 | — | Risk at 7 y AML, 12.4% | Risk at 7 y AML, 12.3% | Comparison TBI versus BuCy Increased risk for CML patients with TBI |
| CML, 47% | CML, 16% | |||||
| Reference . | Type of study . | Patients (N) . | Probability of cataract formation . | Remarks . | ||
|---|---|---|---|---|---|---|
| sTBI . | fTBI . | No TBI . | ||||
| Deeg et al26 | Single center (Seattle) | 277 | 80% at 6 y | 18% at 6 y | 19% at 6 y | Sparing effect of fTBI |
| Tichelli et al27 | Single center (Basel) | 197 | 100% at 3.5 y; surgery 96% | 29% at 3.3 y | TBI | |
| Single dose | ||||||
| 83% at 6 y | Corticosteroids > 3 mo | |||||
| Benyunes et al28 | Single center (Seattle) | 492 | 85% at 11 y | Risk at 11 y 50% (> 12 Gy) | 19% at 11 y | Need of surgical repair 59% sTBI |
| 34% (12 Gy) | 33% fTBI | |||||
| 23% no TBI | ||||||
| Highest yearly hazard of cataract formation earlier with sTBI than fTBI | ||||||
| Belkacemi et al29 | Single center (Paris) | 494 | 34% at 5 y | 11% at 5 y | High dose rate, main risk factor | |
| Belkacemi et al30 | EBMT registry | 1063 | Risk at 10 y 60%; 32% surgery | Risk at 10 y 43%; 3% surgery | — | Risk factors Older age |
| Higher dose rate | ||||||
| Allogeneic SCT | ||||||
| No heparin | ||||||
| Socié et al31 | 4 randomized studies | 488 | — | Risk at 7 y AML, 12.4% | Risk at 7 y AML, 12.3% | Comparison TBI versus BuCy Increased risk for CML patients with TBI |
| CML, 47% | CML, 16% | |||||
TBI indicates total body irradiation; sTBI, single-dose TBI; fTBI, fractionated TBI; BuCy, conditioning with busulfan/cyclophosphamide; Gy, Gray; —, not applicable.